Teva Pharma (TEVA) Tops Q3 EPS by 7c; Boosts FY15 EPS Outlook

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.35, $0.07 better than the analyst estimate of $1.28. Revenue for the quarter came in at $4.8 billion versus the consensus estimate of $4.75 billion.

Teva Pharma sees FY2015 EPS of $5.40-$5.45, versus prior guidance of $5.15-$5.40 and the consensus of $5.32.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• Raytheon Technologies (RTX) Tops Q1 EPS by 11c; reaffirms outlook
• Philip Morris International (PM) Tops Q1 EPS by 9c; raises guidance